Clinical Trials Logo

Filter by:
NCT ID: NCT05306262 Completed - Hypnosis Clinical Trials

Interest of Catalepsy in the Hypnotic Trance

CATALHYPNOANI
Start date: May 26, 2022
Phase: N/A
Study type: Interventional

Catalepsy seems to facilitate hypnotic induction and deepen hypnotic trance, although no work confirms the usefulness of this technique which is in common use in hypnosis. Furthermore, it has been shown that the hypnotic trance state is accompanied by an increase in parasympathetic tone, the non-invasive measurement of which is easy by the ANI monitor (Analgesia Nociception Index). The research hypothesis is that, by adding a body dissociation, catalepsy could facilitate and intensify the hypnotic trance, the intensity of which can be monitored and is proportional to the parasympathetic tone.

NCT ID: NCT05306249 Completed - HIV Seropositivity Clinical Trials

Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients

GALIG-CBD
Start date: May 16, 2022
Phase: Phase 2
Study type: Interventional

Autophagy and apoptosis are natural cellular mechanisms which consist for the first in a recycling and elimination process of potentially toxic cellular waste, and for the second in a process of cellular suicide when it becomes abnormal and "not" repairable, notably by autophagy. A deficit in autophagic function at the cellular level can lead to chronic inflammation and accelerated cellular senescence. Apoptosis is a beneficial phenomenon because it eliminates abnormal cells that could endanger the organism if it survives (e.g. karyotypic atypia). Uncontrolled, it can be deleterious if apoptosis is hypo or hyperactive.

NCT ID: NCT05306106 Completed - Healthy Volunteers Clinical Trials

Glycemic Index of Pastry

IG-DESSERT
Start date: April 6, 2021
Phase: N/A
Study type: Interventional

In the early 1980s and following the first publications by Jenkins et al., The notion of glycemic index (GI) appeared with the aim of classifying the different sources of carbohydrates in our diet according to their effect on the post-prandial glycemic response. Since these years, many studies have been designed to determine the usefulness of the glycemic index and indicate that a low glycemic index for a food, a dish, a meal or a diet is associated with a decreased risk of metabolic pathologies (diabetes, hypertriglyceridemia), degenerative (cardiovascular diseases) or overload (obesity). This justifies the interest in favoring foods with a low glycemic index in healthy subjects. A review confirmed the mechanistic link between postprandial blood sugar and the variability of blood sugar, making it possible, on the one hand, to maintain good glucose homeostasis and, on the other hand, to prevent pathologies such as obesity, diabetes and cardio-vascular diseases. The EFSA also considers that reducing the increase in blood sugar in the post-meal phase can be considered a physiological benefit, especially in subjects with glucose intolerance. Post-meal blood sugar depends on many factors including the glycemic index of foods eaten during the meal. Knowing the glycemic index of foods is therefore very useful. Mademoiselle Dessert offers pastries with a low glycemic index. The objective of this study is thus to determine the glycemic index of 6 pastries in order to inform consumers on these pastries glycemic index.

NCT ID: NCT05306093 Completed - Anhedonia Clinical Trials

Depressed Mood and Anhedonia in Healthy Adults

MOOD5
Start date: January 7, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect of nutraceutical supplement on depressed mood and anhedonia in volunteers after 8 weeks of consumption.

NCT ID: NCT05305794 Active, not recruiting - Double Diabetes Clinical Trials

Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

TOLEDDO
Start date: July 12, 2022
Phase: Phase 3
Study type: Interventional

Between 16% and 22% of type 1 diabetic patients present a clinical and biological profile of insulin resistance favored by a family history of type 2 diabetes or metabolic syndrome. They constitute a group of patients with "double diabetes" since they have both true type 1 diabetes and inherited insulin resistance, typical of type 2 diabetes. For several years, GLP1 agonists have been successfully used in the treatment of type 2 diabetes, leading to very significant improvements in glycemic control and weight loss. Because of the insulin-sensitizing power of GLP1 agonists, the investigators hypothesize that they could reduce insulin resistance in patients with "double diabetes" and thus improve their glycemic control. The investigators propose to use in this study semaglutide, the most recent and most potent GLP1 agonist (superiority demonstrated compared to exenatide LP and dulaglutide) and administered as a weekly subcutaneous injection (in contrast to liraglutide administered daily).

NCT ID: NCT05305157 Recruiting - Dental Caries Clinical Trials

Telemedicine and Forensic Odontology

Start date: March 1, 2022
Phase:
Study type: Observational

The aim of this study is to identify the expectations of experts in forensic odontology on telemedicine. This study could improve, in multiple cases post mortem body identification.

NCT ID: NCT05305144 Active, not recruiting - Clinical trials for Cerebral Small Vessel Diseases

Retinal, Cerebral and Vascular Precursor Markers of Cerebral Small Vessel Disease.

SHIVA-SHARE
Start date: June 7, 2021
Phase: N/A
Study type: Interventional

Cognitive impairment and dementia are primarily due to a combination of vascular brain injury and neurodegenerative lesions. The vascular component is now recognized as a major contributor to the pathophysiology of dementia, with small vessel disease (SVD) being its most frequent substrate. This study aims to collect retinal microvascular markers as well as various parameters related to blood pressure and arterial stiffness, in a young adult population. The main objective is to explore the association between these parameters and structural changes on brain MRI. Results will allow to determine the most relevant biomarkers associated with very early brain imaging markers of SVD.

NCT ID: NCT05305079 Recruiting - Clinical trials for Non-arteritic Ischemic Optic Neuropathy

NA-AION Risk Factors: New Perspectives

NARROW
Start date: August 1, 2021
Phase:
Study type: Observational

The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.

NCT ID: NCT05305040 Terminated - Clinical trials for Cytomegalovirus Infections

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Prevent
Start date: March 24, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

NCT ID: NCT05305014 Completed - Conversion Disorder Clinical Trials

Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder

HYCOIN
Start date: April 1, 2022
Phase:
Study type: Observational

Conversion disorders, also called "dissociative disorders" (ICD-10), or "functional neurological disorders" (DSM-5), are a common condition, with a prevalence of 1-10% in medical and surgical inpatients (Toone 1990), and 10-30% in neurology patients (Carson et al. 2000). They are characterized by the presence of symptoms or deficits affecting voluntary motor, sensory, or sensory functions suggestive of a neurological or general medical condition in combination with psychological factors. Functional neurological disorder is currently a diagnosis of elimination and its treatment remains uncodified. A better understanding of the pathophysiology of this disorder is needed to improve the diagnostic and therapeutic approach to this condition. Identifying new biological markers associated with motor symptoms occurring during the course of the functional neurological disorder would allow clinicians to acquire new diagnostic methods, to improve therapeutic means and their specificity and to highlight possible predictive factors of the clinical evolution of this pathology. At the same time, the identification of biological markers associated with motor symptoms will allow the patient to better understand and accept the diagnosis, and thus to better adhere to the proposed treatment.